Comment from Substance Abuse Program Administrators Association
AnonymousSupportTrade association
Summary: The Substance Abuse Program Administrators Association (SAPAA), a nonprofit trade association, supports the FDA's proposal to exempt certain Class II clinical toxicology devices from premarket notification requirements. They argue that the current regulatory uncertainty hinders the adoption of federal oral fluid drug testing and recommend that the final framework be broad and flexible enough to accommodate emerging drug trends and existing federal testing standards.
SAPAA is resubmitting its comments to ensure they are associated with the correct docket. The comments originally submitted on May 28, 2026, inadvertently referenced an incorrect docket number. No changes have been made to the substance of SAPAA's comments. This resubmission is intended solely to correct the docket reference and ensure the comments are included in the appropriate administrative record.